{
  "docId": "019de515-911d-72b5-80ca-abefe6442528",
  "docSlug": "4384978442320c81c75f03a3e275da5e",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 34 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 34,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 50,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-911d-72b5-80ca-abefe6442528/10",
  "deckHref": "/decks/019de515-911d-72b5-80ca-abefe6442528",
  "deckJsonHref": "/decks/019de515-911d-72b5-80ca-abefe6442528.json",
  "deckAnchorHref": "/decks/019de515-911d-72b5-80ca-abefe6442528#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.18,
        "x": 0.791,
        "y": 0.496
      },
      "kind": "list",
      "text": "FX Headwind in 1Q23:\nRevenue: $31M\nAdj. EBITDA²: $14M",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c58c3737-d77c-4165-8975-0ef8608348fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.18,
        "x": 0.791,
        "y": 0.32
      },
      "kind": "paragraph",
      "text": "1Q22 results were not fully burdened by all stand-up costs associated with the separation",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d935fc4f-a21c-416e-8d01-5fbf0870c5df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.809,
        "x": 0.155,
        "y": 0.879
      },
      "kind": "source-note",
      "text": "1. Products with sales outside the United States impacted by F/X changes.\n2. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.\n3. Includes transactional FX and NCI. Currency headwind (translational and transactional) was $14M to Adj. EBITDA for Q1 2023. The Q1 FY2022 transactional FX impact was a gain of $1M.\n4. 1Q22 presented on an adjusted basis after giving effect to the IPO.\n5. Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n6. 1Q22 results were not fully burdened by all stand-up costs associated with the separation",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03c80f8d-fc1e-4d74-8546-7f657fec8ebd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.74,
        "x": 0.035,
        "y": 0.149
      },
      "kind": "table",
      "text": "Bausch + Lomb, 1Q23, 1Q22, Reported Change, Constant Currency Change, Vision Care Revenue, Surgical Revenue, Ophthalmic Pharmaceuticals Revenue, Total Revenue, Adj. Gross Profit, Adj. Gross Margin, R&D, R&D % of Revenues, Adj. SG&A, Adj. SG&A % of Revenues, Adj. EBITA, Depreciation, Stock Based Compensation, Adj. EBITDA, Adj. EBITDA Margin, Adj. Net Income Attributable to Bausch + Lomb, Adj EPS Attributable to Bausch + Lomb",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "629f2a62-283d-4819-b1d8-4de3aa1037ce",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 10,
      "beatId": "6c09b63c-7240-4f0a-b18b-e5cbeed428e6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The deck provides financial data and guidance for 2023",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 10,
      "name": "Benchmark Gap",
      "slug": "39-benchmark-gap",
      "bestFor": "Performance improvement, competitive analysis, target setting",
      "matchId": "db64b6a9-64be-4ffa-824c-13ab08d6251f",
      "evidence": "The deck provides financial data and guidance for 2023",
      "position": 1,
      "objective": "Show the company's financial performance relative to benchmarks",
      "structure": "Our Performance -> Industry Average -> Best-in-Class -> The Gap = The Opportunity",
      "confidence": 0.7,
      "description": "Compare performance against best-in-class to quantify the opportunity"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}